Compare Amphastar Pharmaceuticals Inc (AMPH) vs Match Group Inc (MTCH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Match Group Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Match Group Inc trades at $39.87 (market cap $9.06B). The key difference: Match Group Inc is far larger — about 11× Amphastar Pharmaceuticals Inc's market cap, and Match Group Inc pays a 2.06% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | MTCH | |
|---|---|---|
Market Cap | $826.08M | $9.06B |
Sector | Health | Media |
52-Week High | $30.81 | $39.32 |
52-Week Low | $16.87 | $28.90 |
Enterprise Value | $1.22B | $12.01B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
MTCH trades at $38.85, down 1.2% today, with a bullish technical signal from moving averages and key support at $38. The company shows solid fundamentals with a P/E of 14.83, net income margin of 18.83%, and three consecutive quarterly earnings beats. Revenue growth remains stable at $3.49B for 2025, while cash flow from operations improved to $1.08B. Recent news highlights a turnaround focus, including Tinder's AI features and Hinge's growth.
The outlook is positive with a consensus price target of $41.63, implying 7% upside. Analyst sentiment is bullish (53% Buy), but risks include high long-term debt of $3.85B and competitive pressures in dating apps. Earnings growth and debt management are critical for sustained stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
